ContraVir Pharmaceuticals将在抗纤维化药物开发峰会上展示CRV431临

StephenW

ContraVir Pharmaceuticals to Present CRV431 Preclinical Data at the Anti-Fibrotic Drug Development Summit

EDISON, N.J., Nov. 27, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of liver disease arising from chronic viral infection and non-alcoholic steatohepatitis, today announced that it will present a poster at the Anti-Fibrotic Drug Development (AAFD) Summit, being held in Cambridge, Massachusetts from November 27-29, 2018.

Daren Ure, PhD, ContraVir’s Director of Research and Development, will present preclinical data of the anti-fibrotic effects of CRV431, the Company’s cyclophilin inhibitor, on liver fibrosis in a model of nonalcoholic steatohepatitis.

Robert Foster, PharmD, PhD, Chief Executive Officer of ContraVir Pharmaceuticals, said, “Having previously demonstrated CRV431’s primarily antiviral mechanism of action, this presentation will review the anti-fibrotic and anti-cancer effects of CRV431, supporting CRV431’s potential to treat a broader range of liver disease.”

Presentation Details

CRV431, A Cyclophilin Inhibitor, Decreases Liver Fibrosis and Tumor Burden in a Mouse Model of Nonalcoholic Steatohepatitis (NASH)
Authors:  Daren Ure1, Joseph Kuo2, Michael Bobardt2, Udayan Chatterji2, Philippe Gallay2, Daniel Trepanier1, Robert Foster1
1Contravir Pharmaceuticals, Edison, NJ and Edmonton, Alberta; 2Scripps Research Institute, La Jolla, CA
Date: November 28, 2018
Location: Hyatt Regency Cambridge

About CRV431

CRV431 is a non-immunosuppressive analog of cyclosporine A (CsA) whose primary biochemical action is inhibition of cyclophilin isomerase activity, playing a key role in protein folding. Other viruses such as HIV-1 and HCV, similarly use cyclophilin for their replication. In pre-clinical studies, CRV431 has shown potential in experimental models to complement current hepatitis B treatments by reducing multiple markers of infection including HBV DNA, HBsAg, HBx, HBeAg, and HBV uptake by cells. Studies have also demonstrated that CRV431 reduces the progression of fibrosis in an animal model and also reduces both the number and size of liver tumors in a hepatocellular carcinoma (HCC) model.

StephenW

ContraVir Pharmaceuticals将在抗纤维化药物开发峰会上展示CRV431临床前数据

EDISON，新泽西州，2018年11月27日（GLOBE NEWSWIRE） - ContraVir Pharmaceuticals，Inc。（纳斯达克股票代码：CTRV），一家生物制药公司，专注于治疗慢性病毒感染引起的肝病治疗药物的开发和商业化。非酒精性脂肪性肝炎，今天宣布它将在2018年11月27日至29日在马萨诸塞州剑桥举行的抗纤维化药物开发（AAFD）峰会上发表一张海报。

ContraVir研究与开发总监Daren Ure博士将在非酒精性脂肪性肝炎模型中提供CRV431（公司的亲环蛋白抑制剂）对肝纤维化的抗纤维化作用的临床前数据。

ContraVir制药公司首席执行官医学博士Robert Foster表示，“此前已经证明了CRV431的主要抗病毒作用机制，本报告将回顾CRV431的抗纤维化和抗癌作用，支持CRV431治疗更广泛的潜力肝病范围。“

演示细节

CRV431，亲环蛋白抑制剂，减少非酒精性脂肪性肝炎（NASH）小鼠模型中的肝纤维化和肿瘤负担
作者：Daren Ure1，Joseph Kuo2，Michael Bobardt2，Udayan Chatterji2，Philippe Gallay2，Daniel Trepanier1，Robert Foster1
1Contravir Pharmaceuticals，Edison，NJ和Edmonton，Alberta; 2Scripps研究所，加利福尼亚州拉霍亚
日期：2018年11月28日
地点：剑桥凯悦酒店

关于CRV431

CRV431是环孢菌素A（CsA）的非免疫抑制类似物，其主要生化作用是抑制亲环蛋白异构酶活性，在蛋白质折叠中起关键作用。其他病毒如HIV-1和HCV类似地使用亲环蛋白进行复制。在临床前研究中，CRV431在实验模型中显示出通过减少多种感染标志来补充当前乙型肝炎治疗的潜力，包括HBV DNA，HBsAg，HBx，HBeAg和HBV细胞摄取。研究还表明，CRV431减少了动物模型中纤维化的进展，并且还降低了肝细胞癌（HCC）模型中肝肿瘤的数量和大小。

春景

这药看来有效，看进度了

hp121

回复 春景 的帖子

临床前

要看是否有效，起码二期完成，最快也得两年才知道

齐欢畅

CRV431（公司的亲环蛋白抑制剂）

hp121

都是实验模型而已

当然，希望成功